ExploreWatchlistsPricing
  1. US-listed companies
  2. Adaptimmune Therapeutics PLC
  3. Financials
  4. Marketable securities, current

Adaptimmune Therapeutics PLC (ADAPY)

Market cap
$5.73M
P/E ratio
SummaryFinancials
Period EndMarketable securities, current (Million USD)YoY (%)
Dec 31, 202460+1951.78%
Dec 31, 20233-96.95%
Dec 31, 202297-56.03%
Dec 31, 2021220-29.45%
Dec 31, 2020311+695.64%
Dec 31, 201939-71.39%
Dec 31, 2018137+10.09%
Dec 31, 2017124

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat